Momeni A Z, Aminjavaheri M
Department of Dermatology, Isfahan University of Medical Sciences, Iran.
Int J Dermatol. 1995 Feb;34(2):129-33. doi: 10.1111/j.1365-4362.1995.tb03598.x.
Cutaneous leishmaniasis is endemic in Iran. One of the clinical pictures of this disease is leishmaniasis recidivans (LR). Most of the drugs used for cutaneous leishmaniasis are ineffective in LR.
Twenty-five patients (13 women and 12 men), who had LR and whose disease had been proved by previous direct smears, were accepted for the study. The duration of disease in all patients was more than 2 years and they had previously been treated for their cutaneous leishmaniasis by different methods. All patients were treated with a combination of allopurinol (AL) (20 mg/kg/day for 30 days) and meglumine antimoniate (MA) (70 mg/kg/day for 15 days). Laboratory tests including hemograms, liver function, and kidney function tests, were done both at baseline and at the end of therapy.
Twenty-four out of 25 patients (96%) responded well to treatment and after 1 year follow-up no relapse had occurred. The drugs were well tolerated by the patients producing no side effects nor any significant changes in laboratory values.
A combination of AL and antimoniate is an effective method for the treatment of LR and for patients with cutaneous leishmaniasis who are resistant to the usual treatments.
皮肤利什曼病在伊朗为地方病。该疾病的临床症状之一是复发性利什曼病（LR）。大多数用于治疗皮肤利什曼病的药物对LR无效。
本研究纳入了25例LR患者（13例女性和12例男性），其疾病已通过先前的直接涂片检查得到证实。所有患者的病程均超过2年，且他们之前曾采用不同方法治疗过皮肤利什曼病。所有患者均接受别嘌醇（AL）（20mg/kg/天，共30天）和葡甲胺锑酸盐（MA）（70mg/kg/天，共15天）联合治疗。在基线期和治疗结束时均进行了包括血常规、肝功能和肾功能检查在内的实验室检测。
25例患者中有24例（96%）对治疗反应良好，随访1年后未出现复发。患者对药物耐受性良好，未产生副作用，实验室检查值也未出现任何显著变化。
AL与锑酸盐联合使用是治疗LR以及对常规治疗耐药的皮肤利什曼病患者的有效方法。
